Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.0090 AUD
Change Today 0.00 / 0.00%
Volume 1.2M
As of 11:05 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

imugene ltd (IMU) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/22/14 - A$0.02
52 Week Low
08/25/15 - A$0.0070
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMUGENE LTD (IMU)

Related News

No related news articles were found.

imugene ltd (IMU) Related Businessweek News

No Related Businessweek News Found

imugene ltd (IMU) Details

Imugene Limited, an immuno-oncology biopharmaceutical company, together with its subsidiaries, engages in the research and development of HER2 +ve gastric and breast cancer immunotherapies in Australia. Its lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. HER2/neu is a known and validated receptor over-expressed on various tumours, including gastric, breast, ovarian, lung, and pancreatic cancers. HER-Vaxx has completed a Phase I study in breast cancer and focuses on a Phase Ib/II study in gastric cancer. Imugene Limited is based in Armadale, Australia.

imugene ltd (IMU) Top Compensated Officers

Managing Director, Director, Member of Audit ...
Total Annual Compensation: A$162.5K
Chief Financial Officer and Joint Company Sec...
Total Annual Compensation: A$124.8K
Head of Manufacturing & Operations, Member of...
Total Annual Compensation: A$188.8K
Joint Company Secretary
Total Annual Compensation: A$12.0K
Compensation as of Fiscal Year 2015.

imugene ltd (IMU) Key Developments

Imugene Ltd. Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2015

Imugene Ltd. reported audited consolidated earnings results for the year ended June 30, 2015. For the year, the company reported revenue was AUD 38,355 against AUD 27,101 for the same period last year. Other income was AUD 600,321 against AUD 511,211 for the same period last year. Loss before tax was AUD 2,440,789 against AUD 2,115,964 for the same period last year. Net loss after income tax was AUD 2,440,789 or 0.21 cents per basic and diluted share against AUD 2,115,964 or 0.31 cents per basic and diluted share for the same period last year. Net cash outflows from operating activities were AUD 2,043,584 against AUD 1,144,098 for the same period last year. Payment for the purchase of IP was AUD 463,617 against AUD 600,187 for the same period last year.

Imugene Limited Announces Management Changes

Imugene Limited appointed Ms. Leslie Chong as COO, effective mid September 2015. Most recently, Ms. Chong was a Senior Clinical Program Leader at Genentech Inc., in San Francisco. Currently based in San Francisco, Ms. Chong will relocate to Sydney within the month. Also, Managing Director Mr. Charles Walker will step down as Managing Director and continue his involvement as a non-executive director of Imugene.

Imugene Appoints Ursula Wiedermann as Chief Scientific Officer

Imugene Ltd. has appointed University Prof. Dr. Ursula Wiedermann as Chief Scientific Officer (CSO) of the company. Prof. Dr. Wiedermann has worked as the Principal Investigator for the preclinical development of HER-Vaxx alongside Professor Christophe Zielinski, and currently serves on the Company's scientific advisory board. Together they performed the Phase I Clinical trial of HER-Vaxx in metastatic breast cancer patients.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMU:AU A$0.01 AUD 0.00

IMU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMU.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.4x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMUGENE LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at